Search Results

There are 12024 results for: content related to: Entacapone to tolcapone switch: Multicenter double-blind, randomized, active-controlled trial in advanced Parkinson's disease

  1. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease

    Intervention Review

    The Cochrane Library

    Katherine Deane, Sybille Spieker and Carl E Clarke

    Published Online : 18 OCT 2004, DOI: 10.1002/14651858.CD004554.pub2

  2. Evidence-Based Efficacy Comparison of Tolcapone and Entacapone as Adjunctive Therapy in Parkinson's Disease

    CNS Neuroscience & Therapeutics

    Volume 14, Issue 1, Spring 2008, Pages: 83–93, Andrew J. Lees

    Version of Record online : 14 MAR 2008, DOI: 10.1111/j.1527-3458.2007.00035.x

  3. You have full text access to this OnlineOpen article
    Elucidating Differences in the Hepatotoxic Potential of Tolcapone and Entacapone With DILIsym®, a Mechanistic Model of Drug-Induced Liver Injury

    CPT: Pharmacometrics & Systems Pharmacology

    Volume 5, Issue 1, January 2016, Pages: 31–39, DM Longo, Y Yang, PB Watkins, BA Howell and SQ Siler

    Version of Record online : 13 JAN 2016, DOI: 10.1002/psp4.12053

  4. Catechol-O-Methyltransferase (COMT) Inhibitors in Parkinson's Disease

    Journal of the American Geriatrics Society

    Volume 48, Issue 6, June 2000, Pages: 692–698, Cheryl Waters

    Version of Record online : 27 APR 2015, DOI: 10.1111/j.1532-5415.2000.tb04732.x

  5. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson´s disease patients with motor complications

    Intervention Review

    The Cochrane Library

    Rebecca Stowe, Natalie Ives, Carl E Clarke, Katherine Deane, van Hilten, Keith Wheatley, Richard Gray, Kelly Handley and Alex Furmston

    Published Online : 7 JUL 2010, DOI: 10.1002/14651858.CD007166.pub2

  6. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease

    Movement Disorders

    Volume 26, Issue S3, October 2011, Pages: S2–S41, Susan H. Fox, Regina Katzenschlager, Shen-Yang Lim, Bernard Ravina, Klaus Seppi, Miguel Coelho, Werner Poewe, Olivier Rascol, Christopher G. Goetz and Cristina Sampaio

    Version of Record online : 21 OCT 2011, DOI: 10.1002/mds.23829

  7. You have free access to this content
    Catechol-O-methyltransferase and Its Inhibitors in Parkinson's Disease

    CNS Drug Reviews

    Volume 13, Issue 3, Fall 2007, Pages: 352–379, Maria João Bonifácio, P. Nuno Palma, Luís Almeida and Patrício Soares-da-Silva

    Version of Record online : 24 SEP 2007, DOI: 10.1111/j.1527-3458.2007.00020.x

  8. You have free access to this content
    Pharmacodynamic Response of Entacapone in Rats after Administration of Entacapone Formulations and Prodrugs with Varying Bioavailabilities

    Pharmacology & Toxicology

    Volume 90, Issue 6, June 2002, Pages: 327–332, Markus Forsberg, Jouko Savolainen, Tomi Järvinen, Jukka Leppänen, Jukka Gynther and Pekka T. Männistö

    Version of Record online : 1 JUL 2002, DOI: 10.1034/j.1600-0773.2002.900606.x

  9. Development of a physiologically based pharmacokinetic/pharmacodynamic model to identify mechanisms contributing to entacapone low bioavailability

    Biopharmaceutics & Drug Disposition

    Volume 36, Issue 9, December 2015, Pages: 587–602, Saeed Alqahtani and Amal Kaddoumi

    Version of Record online : 24 DEC 2015, DOI: 10.1002/bdd.1986

  10. You have free access to this content
    Pharmacological profile of opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat

    British Journal of Pharmacology

    Volume 172, Issue 7, April 2015, Pages: 1739–1752, M J Bonifácio, L Torrão, A I Loureiro, P N Palma, L C Wright and P Soares-da-Silva

    Version of Record online : 20 JAN 2015, DOI: 10.1111/bph.13020

  11. Pooled analysis of phase III with entacapone in Parkinson's disease

    Acta Neurologica Scandinavica

    Volume 130, Issue 4, October 2014, Pages: 239–247, M. Kuoppamäki, M. Vahteristo, J. Ellmén and K. Kieburtz

    Version of Record online : 3 SEP 2014, DOI: 10.1111/ane.12278

  12. The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease

    European Journal of Neurology

    Volume 10, Issue 2, March 2003, Pages: 137–146, J. P. Larsen, J. Worm-Petersen, Å. Sidén, A. Gordin, K. Reinikainen, M. Leinonen and the NOMESAFE Study Group

    Version of Record online : 26 FEB 2003, DOI: 10.1046/j.1468-1331.2003.00559.x

  13. Improving l-dopa therapy: The development of enzyme inhibitors

    Movement Disorders

    Volume 30, Issue 1, January 2015, Pages: 103–113, Oscar S. Gershanik

    Version of Record online : 21 OCT 2014, DOI: 10.1002/mds.26050

  14. Twelve-month safety of entacapone in patients with Parkinson’s disease

    European Journal of Neurology

    Volume 8, Issue 1, January 2001, Pages: 53–60, V. V. Myllylä, E.-R. Kultalahti, H. Haapaniemi, M. Leinonen and FILOMEN Study Group

    Version of Record online : 21 DEC 2001, DOI: 10.1046/j.1468-1331.2001.00168.x

  15. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal Levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study)

    Acta Neurologica Scandinavica

    Volume 105, Issue 4, April 2002, Pages: 245–255, W. H. Poewe, G. Deuschl, A. Gordin, E.-R. Kultalahti, M. Leinonen and the Celomen Study Group

    Version of Record online : 3 APR 2002, DOI: 10.1034/j.1600-0404.2002.1o174.x

  16. Use of catechol-O-methyltransferase inhibition to minimize L-3,4-dihydroxyphenylalanine-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque

    European Journal of Neuroscience

    Volume 37, Issue 5, March 2013, Pages: 831–838, Philippe Huot, Tom H. Johnston, Tessa Snoeren, James B. Koprich, Michael P. Hill, Susan H. Fox and Jonathan M. Brotchie

    Version of Record online : 3 JAN 2013, DOI: 10.1111/ejn.12093

  17. Entacapone promotes cAMP-dependent colonic Cl secretion in rats

    Neurogastroenterology & Motility

    Volume 23, Issue 7, July 2011, Pages: 657–e277, L.-S. Li, L.-F. Zheng, J.-D. Xu, T. Ji, H. Guo, X.-F. Li, Y. Li, Y. Zhang and J.-X. Zhu

    Version of Record online : 19 APR 2011, DOI: 10.1111/j.1365-2982.2011.01715.x

  18. Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial

    European Journal of Neurology

    Volume 19, Issue 6, June 2012, Pages: 820–826, D. Nyholm, A. Johansson, H. Lennernäs and H. Askmark

    Version of Record online : 5 DEC 2011, DOI: 10.1111/j.1468-1331.2011.03614.x

  19. You have free access to this content
    Entacapone improves the availability of l-dopa in plasma by decreasing its peripheral metabolism independent of l-dopa/carbidopa dose

    British Journal of Clinical Pharmacology

    Volume 54, Issue 4, October 2002, Pages: 363–371, Helena Heikkinen, Anu Varhe, Tarmo Laine, Jaakko Puttonen, Marjo Kela, Seppo Kaakkola and Kari Reinikainen

    Version of Record online : 23 OCT 2002, DOI: 10.1046/j.1365-2125.2002.01654.x

  20. You have free access to this content
    Endothelial dysfunction in gestational hypertension induced by catechol-O-methyltransferase inhibition

    Experimental Physiology

    Volume 98, Issue 3, March 2013, Pages: 856–866, M. Hernandez, I. Hernandez, F. Rodriguez, M. Pertegal, B. Bonacasa, M. G. Salom, T. Quesada and F. J. Fenoy

    Version of Record online : 23 JAN 2013, DOI: 10.1113/expphysiol.2012.067389